Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Reaffirmed as Buy by HC Wainwright

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $120.00 price target on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 107.53% from the company’s previous close.

A number of other analysts have also recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 17th. B. Riley Financial lifted their price target on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Morgan Stanley lifted their price target on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Citigroup assumed coverage on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 8th. They set a “buy” rating and a $108.00 price target for the company. Ten research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $98.31.

Arrowhead Pharmaceuticals Stock Performance

ARWR stock opened at $57.82 on Thursday. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The firm has a market cap of $8.15 billion, a price-to-earnings ratio of -25.75 and a beta of 1.29. The business’s fifty day simple moving average is $76.71 and its two-hundred day simple moving average is $75.99. Arrowhead Pharmaceuticals has a twelve month low of $36.57 and a twelve month high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The firm had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company’s revenue for the quarter was up 171.0% on a year-over-year basis. During the same period last year, the firm earned ($1.26) earnings per share. Analysts predict that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Michael Perry sold 11,600 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the sale, the director directly owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This represents a 9.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Adeoye Olukotun sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the transaction, the director owned 31,600 shares in the company, valued at approximately $2,747,936. This trade represents a 5.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ARWR. Carolina Wealth Advisors LLC increased its stake in shares of Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after buying an additional 154 shares during the last quarter. First Horizon Corp increased its holdings in shares of Arrowhead Pharmaceuticals by 36.3% in the 1st quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 174 shares during the period. Optiver Holding B.V. grew its stake in shares of Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares in the last quarter. Versant Capital Management Inc lifted its position in Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares during the period. Finally, QRG Capital Management Inc. lifted its stake in Arrowhead Pharmaceuticals by 7.1% during the second quarter. QRG Capital Management Inc. now owns 4,810 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 317 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: ARO-MAPT produced deep and durable reductions in tau, reaching as much as 73% in healthy volunteers. Arrowhead said the study marks the first successful clinical demonstration of its platform achieving substantial target-gene knockdown in the brain, a potentially important milestone for its central-nervous-system pipeline. Arrowhead ARO-MAPT interim clinical data
• Positive Sentiment: The Alzheimer’s candidate’s ability to cross the blood-brain barrier and reduce tau is driving investor enthusiasm, although the current evidence is limited to an early-stage study in healthy volunteers. Positive ARO-MAPT Phase 1/2a data
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $120 price target, implying substantial upside from the provided $58.37 reference price. The target reflects increased optimism around ARO-MAPT and Arrowhead’s broader CNS pipeline.
• Neutral Sentiment: Management discussed ARO-MAPT’s interim findings and the TRiM CNS delivery platform, highlighting potential pipeline expansion into additional neurological diseases. Arrowhead ARO-MAPT and TRiM discussion
• Negative Sentiment: The data remain preliminary and were generated in healthy volunteers, so they do not yet establish that ARO-MAPT improves cognition or slows Alzheimer’s progression. Further clinical testing and confirmation in patients will be necessary.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.